Drug Trial Radar · NCT05518578
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 7, 2023
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures
Conditions
- Epilepsy
- Seizures, Epileptic
Interventions
SPN-817Drug
oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effects of SPN-817 on safety and tolerabilityTime frame: 72 weeks
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Green Leaf Clinical Trials, LLC
Jacksonville, Florida · Recruiting
Visionary Investigators Network
Miami, Florida · Recruiting
Prince of Wales Hospital
Randwick, New South Wales, Australia · Recruiting
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia · Completed
Westmead Hospital
Sydney, New South Wales, Australia · Completed
Royal Brisbane and Women's Hospital
Brisbane, Queensland, Australia · Recruiting
Box Hill Hospital
Box Hill, Victoria, Australia · Recruiting
The Austin Hospital
Heidelberg, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
The Royal Melbourne Hospital
Parkville, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.